Merrill Lynch Br. SmallerCo Tst PLC
16 February 2007
MERRILL LYNCH BRITISH SMALLER COMPANIES TRUST plc
All information is at 31 January 2006 and unaudited.
Performance at month end is calculated on a capital only basis
One Three One Three Five
Month Months Year Years Years
Net asset value 2.5% 13.9% 27.6% 96.0% 103.6%
Share price 2.2% 12.4% 27.1% 118.6% 113.9%
FTSE SmallCap Index (ex IC's) 0.9% 9.6% 14.6% 45.7% 53.8%
Sources: BlackRock and Datastream.
At month end
Net asset value: 443.67p
Share price: 379.75p
Discount to NAV: 14.4%
Net yield: 1.2%
Total assets: £240.6m
Gearing: 8.5%
Ordinary shares in issue: 49,993,523
Ten Largest Sector
Weightings % of Total Assets
Support Services 16.5
Real Estate 10.6
Software & Computer Services 9.0
General Financial 7.3
Industrial Engineering 6.8
Electronic & Electrical Equipment 5.6
Oil & Gas Producers 5.3
Media 5.3
Non-Life Insurance 4.9
Mining 3.6
----
Total 74.9
----
Ten Largest Equity Investments (in alphabetical order)
Company
Aveva Group
Brewin Dolphin
BSS Group
Chaucer Holdings
Dechra Pharmaceuticals
Domino Printing
ITE Group
Mouchel Parkman
Rathbone Brothers
WSP Group
Commenting on the markets, Mike Prentis, representing the Investment Manager
noted:
The Company's NAV rose by 2.5% in January on a capital only basis. The benchmark
index rose by 0.9%.
The main positive contributors to relative performance in January were the
Company's holdings in Dechra Pharmaceuticals, Plant Health Care and Aveva.
Dechra, who develop and distribute a wide range of pharmaceutical products used
by vets, released a positive post half year end trading update which received
good broker coverage. Plant Health Care signed a license with Bayer CropScience
allowing Bayer to sell its Myconate product in connection with certain crop
types. In the medium term this agreement should generate substantial profits for
Plant Health Care. Aveva shares continued to rise, reflecting the sustained
strength in its end markets. Good absolute share price performances came from a
few smaller holdings notably KBC Advanced Technology (up 51%), and City of
London Investment Group (up 21%).
The largest negative impact on relative performance in January came from
holdings in SMC and Speedy Hire. SMC announced a change in accounting policy to
adopt a more cautious line - this was in effect a profit warning, although
management assure us that trading is resilient. In early February we visited
Speedy Hire at its head office and several depots in the North West. This was
very comforting and confirmed trading remains in line with expectations.
The main new holding in the month was software company Micro Focus. This
holding was acquired in advance of a trading update which was expected to be
good and lived up to expectations. Holdings in Findel and Unite were sold after
good runs.
Newsflow from the portfolio continues to be generally positive. In addition to
earnings upgrades, we are seeing continued M & A activity. We are expecting a
good round of results from portfolio companies later this month and in the first
half of March.
Latest information is available by typing www.blackrock.co.uk/its on the
internet, 'BLRKINDEX' on Reuters, 'BLRK' on Bloomberg or '8800' on Topic 3 (ICV
terminal).
16 February 2007
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.